p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases.
Although clinical and histological criteria for ependymoma prognosis are recognized, studies have reported contradictory results. Prognostic significance based on immunohistochemistry of ependymomas has been described in a few studies and a strong prognostic value of p53 aberrant expression has been established. Recently, p53 regulation has found to be dependent on the function of the pl4ARF gene product, which has been shown to be critically involved in human carcinogenesis. In this study we have examined patients with intracranial ependymomas (n=103) for immunoexpression of the novel antibody FL-132 to human pl4ARF protein. We found that: (1) the polyclonal FL-132 antibody seems to be suitable for studying pl4ARF protein status in routinely processed and paraffin-embedded specimens; (2) decreasing pl4ARF protein expression is associated with patterns of ependymoma biological aggressiveness, i.e., increasing tumor grade, elevated growth fraction and p53 protein accumulation; however, there was no any association between p14 and MDM2 immunoexpression in ependymomas; (3) although the biological events underlying pl4ARF inactivation in ependymal neoplasms are still unclear, FL-132 immunohistochemistry appears to be useful for assessing an individual prognosis in these tumors; when the p14 score was considered as "high" versus "low" (cut-off p14 labeling index at 10%), it represented an independent prognostic factor in both univariate and multivariate analyses (hazard ratio -3.56; P=0.0003); and (4) most beneficial information for evaluation of malignant ependymoma outcome should be elicited from simultaneous immunohistochemical investigation of p14 ARF and p53 in tumor specimen.
Korshunov
A
A
Department of Neuropathology, Neurosurgical NN Burdenko Institute, Moscow, Russia. akorshunov@nsi.ru
Golanov
A
A
Timirgaz
V
V
D000293:Adolescent; D000328:Adult; D000951:Antigens, Neoplasm / Q000276:immunology; D001932:Brain Neoplasms / Q000276:immunology* / Q000473:pathology*; D002648:Child; D004250:DNA Topoisomerases, Type II / Q000276:immunology; D004268:DNA-Binding Proteins; D015536:Down-Regulation / Q000276:immunology; D004806:Ependymoma / Q000276:immunology* / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000276:immunology; D009687:Nuclear Proteins; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000276:immunology; D051736:Proto-Oncogene Proteins c-mdm2; D016019:Survival Analysis; D025803:Tumor Suppressor Protein p14ARF / Q000276:immunology*; D016159:Tumor Suppressor Protein p53 / Q000276:immunology
D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D025803:Tumor Suppressor Protein p14ARF; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D004250:DNA Topoisomerases, Type II